Curative effect of dabigatran in elderly patients with non-valvular atrial fibrillation and different ;creatinine clearance rate
ZHANG Wei
WANG Xiao-bing
WU Yun-tao
YAO Lu
TIAN Guo-xiang
Abstract：Objective To observe the curative effect and safety of dabigatran in elderly patients with non-valvular atrial fibrillation (NVAF) and different creatinine clearance rate (CCr). Methods The patients (n=36) were, according to kidney function, divided into compensated group (CCr from 51 mL/min to 70 mL/min, n=19) and decompensated group (CCr from 31 mL/min to 50 mL/min, n=17), and 2 groups were given dabigatran in different doses respectively (110 mg bid and 110 mg qd). The changes of coagulation indexes, liver function and kidney function were detected at different time points (before and 1 m, 3 m and 6 m after treatment). The incidence of major adverse cardiovascular events (MACE) and drug adverse reactions were observed after treatment for 6 m. Results After treatment for 1 m, 3 m and 6 m, prothrombin time (PT), activated partial thromboplastin time (APTT) and thrombin time (TT) were prolonged gradually than before (P<0.05) in 2 groups. PT, APTT and TT had statistical difference after treatment for 3 m and 6 m compared with those after treatment for 1 m (P<0.05) in 2 groups. The difference in CCr, international normalized ratio (INR) and D-dimer had no statistical significance before and after treatment (P>0.05), and indexes of liver function and kidney function had no significant changes in 2 groups. There were no MACE and bleeding events observed in 2 groups after treatment for 6 m. Conclusion Dabigatran is administrated in different doses according to kidney function will reduce the risk of embolism and bleeding in elderly patients.
Keywords：DabigatranCoagulation functionElderly patientsNon-valvular atrial fibrillation
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 328-330 )